Mangalam Drugs and Organics Balance Sheet
- Market cap
- ₹50.65 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹23.04 – ₹43.20
As of FY25, Mangalam Drugs and Organics had total assets of ₹32.92 crore and borrowings of ₹6.08 crore, against shareholders' equity of ₹143 crore — a debt-to-equity ratio of 0.35.
Mangalam Drugs and Organics balance sheet
As at each financial year end, newest first. H1 = half-year.
| Item | FY25 |
|---|---|
| Equity capital | 120 |
| Reserves | 22.79 |
| Borrowings | 6.08 |
| Other liabilities | 4.05 |
| Total liabilities | 32.92 |
| Fixed assets | 17.73 |
| Capital work in progress | 45 |
| Investments | 7.6 |
| Other assets | 7.6 |
| Total assets | 32.92 |
Balance sheet ratios
- Debt to equity
- 0.35
- Book value per share
- ₹11.23
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Mangalam Drugs and Organics balance sheet — frequently asked questions
What is the total debt of Mangalam Drugs and Organics?
Mangalam Drugs and Organics reported borrowings of ₹6.08 crore as of FY25.
What is Mangalam Drugs and Organics' debt-to-equity ratio?
Based on the FY25 balance sheet, Mangalam Drugs and Organics' debt-to-equity ratio is 0.35 — borrowings of ₹6.08 crore against equity capital and reserves of ₹143 crore.
What are Mangalam Drugs and Organics' total assets?
Mangalam Drugs and Organics' total assets were ₹32.92 crore as of FY25, including fixed assets of ₹17.73 crore and investments of ₹7.6 crore.
What is the book value per share of Mangalam Drugs and Organics?
The book value per share of Mangalam Drugs and Organics is ₹11.23, based on the latest reported balance sheet.
Same Data For Peers
Trade Mangalam Drugs and Organics With ATS
Track MANGALAM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.